

The UK Myeloma Society

England & Wales · Charity number 1082702

Details

Other names	THE UK MYELOMA FORUM, UKMF, UKMS
Status	Registered
Legal form	Other
Registered	2000-09-29
Register	View on the Charity Commission register

Contact

Address	Menzies LLP London 4th Floor 95 Gresham Street London EC2V 7AB
Phone	01924 317114
Email	johnashcroft@doctors.org.uk
Website	www.ukmyelomasociety.org.uk

Activities

Objects: 1. THE ADVANCEMENT OF EDUCATION OF THE GENERAL PUBLIC, IN PARTICULAR IN THE TREATMENT OF THOSE SUFFERING FROM MYELOMA AND RELATED DISORDERS, THROUGH THE PROMOTION AND CONDUCT OF RESEARCH AND THE PUBLICATION AND DISSEMINATION OF ALL USEFUL RESULTS OF SUCH RESEARCH. 2. THE RELIEF OF PERSONS SUFFERING FROM MYELOMA AND RELATED DISORDERS, IN PARTICULAR BY (A) THE DEVELOPMENT AND PROVISION OF POLICY GUIDELINES FOR THEIR TREATMENT (B) PROMOTING AN UNDERSTANDING OF THE ISSUES RELATING TO MYELOMA AND RELATED DISEASES BY ENCOURAGING COMMUNICATION AND EXCHANGE OF INFORMATION BETWEEN RESEARCH GROUPS AND HEALTHCARE PROFESSIONALS.

Activities: The education of the public, particularly in the treatment of myeloma, through the promotion of research and the dissemination of results. Also, the relief of persons suffering from myeloma by the development and provision of guidelines for treatment, and promoting an understanding of issues relating to myeloma by encouraging communication between research groups and healthcare professionals.

Classification

- **How:** Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Defined Groups

Geography

- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£190,212	£151,906	-	-
2024-03-31	£137,517	£117,557	-	-
2023-03-31	£137,026	£110,517	-	-
2022-03-31	£125,605	£74,617	-	-
2021-03-31	£137,923	£54,765	-	-

Trustees

Name	Role	Appointed
Catherine Loughran		2024-11-14
Dr Ceri Bygrave		2015-11-01
Dr John Ashcroft		2015-11-01
Dr Jonathan Sive		2020-01-01
Dr KARTHIKEYAN RAMASAMY		2014-11-01
Dr Martin Kaiser		2018-01-01
Dr Matthew Jenner		2018-03-01
Dr Michelle Lawson		2020-01-01
Dr NEIL RABIN		2013-01-22
Dr Rachel Hall		2019-11-01
Dr Rakesh Popat		2018-11-01
Dr Richard Soutar		2017-12-01
Dr Sally Moore		2023-01-31
Dr Sarah Lawless		2018-01-01
Dr Tracey Chan		2024-11-14
Dr jennifer travers		2023-11-14
PROFESSOR GORDON COOK		
Professor Guy Pratt		2013-11-01
jackie quinn		2023-11-14

The UK Myeloma Society

England & Wales - Charity number 1082702

Accounts

TRUSTEES' REPORT AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2025

THE UK MYELOMA
SOCIETY

MENZIES
BRIGHTER THINKING

THE UK MYELOMA SOCIETY

CONTENTS

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 16

THE UK MYELOMA SOCIETY

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2025

Trustees	Dr N Rabin
	Dr C Bygrave
	Dr R Hall
	Dr J Ashcroft
	Prof G Cook
	Prof G Pratt
	Prof M Kaiser
	Dr K Ramasamy
	Dr R Popat
	Dr M Jenner
	Dr J Sive
	Dr S Lawless
	Dr R Soutar
	Dr S Lawson
	J Quinn
	Dr J Travers
	C Loughran
	Dr S Moore
	Dr T Chan (appointed 13 November 2024)
Charity registered number	1082702
Principal office	Pathology Building, Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield WF1 4DG
Independent examiner	Menzies LLP Chartered Accountants Magna House 18-32 London Road Staines-Upon-Thames TW18 4BP
Bankers	Coutts & Co 440 Strand London WC2R 0QS

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2025

The Trustees present their annual report together with the financial statements of the Charity for the 1 April 2024 to 31 March 2025.

Objectives and activities

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

- Developing and promoting clinical trials of myeloma treatment and linked scientific studies
- Encouraging collaborative research and innovation in myeloma
- Developing guidelines for the management of patients with myeloma
- Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
- Promoting patient access to treatment through advocacy and working with stakeholders and partners

The UKMS had a further active year in pursuit of its' charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2024; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

Revenue

- Revenue received for corporate sponsorship contributed £112,420 (April 2024 - March 2025). This re-enforces the support by pharma for the work that the UKMS undertakes
- Separately, £33,000 was raised by Hartley Taylor Medical Communications Ltd from pharma (GSK, J&J, Sanofi x £10k + Amgen £3k) to support for the UKMRA Away Day on the 16 - 17 January 2025 in York
- In addition, £5,250 was raised from Pharma for the UKMS Pharmacy Education Day on the 5 November 2024 at the Wellcome Collection (Sanofi £1,500, J&J £1,750, Menarini Stemline £1,500, BMS £250 and Pfizer £250)

Education

The Autumn Day was held on 14th November 2024, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was 'UK Myeloma Society at 25: Achievements and Future Directions' and featured Professor Gordon Cook from the University of Leeds. He presented the Michael Morley Lecture on Frailty in Myeloma.

The Spring Day was also a hybrid meeting and was held on 19th March 2025. The theme for this meeting was the 'Optimising Outcomes in Myeloma'. The plenary lecture was given by Professor Sigurður Kristinnsson from the University of Iceland. His talk was entitled, 'Results from the Iceland screens, treats or prevents multiple myeloma (iStopMM) study.

Travel Bursaries

A total of six travel bursaries for scientific conferences were awarded in 2024 to winning abstracts;

- 2 x ASH San Diego £1,200 each
- 2 x EHA Madrid £900 each
- 2 X IMS Rio de Janeiro £1,200 each

The abstracts were presented at the subsequent Autumn / Spring Days in either November 2024 or March 2025. A corresponding conference report was also written by the bursary recipients from ASH, EHA and IMS which appeared in the UKMS e-newsletter.

Achievements and performance

Education: The annual meetings

Production of two successful and well attended educational hybrid meetings in November 2024 and March 2025. For full programme details, please refer to the section above and the UKMS website.

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Travel Bursaries for scientific meetings

The UKMS in collaboration with the Michael Morley Fund awarded 6 bursaries in 2024-25 to support the attendance of investigators, scientists, specialist nurses and pharmacists at ASH (American Society of Haematology), IMS (International Myeloma Society) and EHA (European Haematology Association) meetings in 2024-25. Further details can be found above.

Advocacy

The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

The Guidelines group

The UKMS Guidelines Group, Chaired by Dr Simon Stern published in 2023 the MGUS good practice paper (GPP). Another GPP on smouldering myeloma was published early in 2024 in the British Journal of Haematology (BJH). GPPs on imaging in myeloma and high risk disease in transplant-eligible myeloma have been completed and accepted by the BSH Haem-onc Task Force and Guidelines Committee. They have both been submitted to the BJH for publication. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients.

Other guidelines are work in progress, notably guidelines on the management of relapsed myeloma and a GPP on MGRS. Other guidelines in their early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting.

There have been three important guidelines published in the British Journal of Haematology. These include the good practice papers on imaging and high-risk myeloma and the guideline on the diagnosis and management of monoclonal gammopathy of renal significance. These are also available for viewing on the BSH and UKMS web sites.

The guidelines on relapsed/refractory myeloma and amyloidosis screening; the management of myeloma bone disease and the use of bispecific antibodies in relapsed/refractory myeloma also in the early stages of planning.

Dr Simon Stern has stepped down as the Chair of the UKMS Guidelines Group and Dr Tracey Chan has taken over as Chair from March 2025.

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all UK based myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group met three times over the course of the year, twice virtually with one in-person/ hybrid meeting at the Wellcome Collection in central London on the 14th May 2024. On the 16 - 17 January 2025, the UKMRA held the annual Away Day at the Principle Hotel in York. Around 40 clinical trial investigators from across the UK held their main group meeting as well as a full day dedicated to developing UK Myeloma related clinical trials.

Myeloma Nurse Group

Jackie Quinn has chaired the Nurse group since November 2023.

Projects and discussion for 2024 included;

- Develop protocol for Self-administration of Velcade
- Explored the potential for nurse webinars co-partnered with Myeloma UK
- Worked with Myeloma UK to produce a nurse network to support all haematology CNSs across the UK
- The inaugural Nurse Education Study Day took place on 11 March 2025 at the Wellcome Collection
- The group continue to work with the Pharmacy group adapting an online tool Myeloma treatment scheduler called 'MyeTx Scheduler' which is tool to create an individual MM treatment schedule to aid understanding and compliance

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Catherine Loughran will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. On the 5 November 2024, the group held the Pharmacy Education Day at the Wellcome Collection in central London.

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2024 fellows: Sarah Henshaw
Professor Jamie Cavenagh
Dr John Ashcroft

Financial review

The UKMS's policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Income

- Education Grants from Corporate Sponsors contributed approximately £112,420 in 2024
- Income from Pharmacy Day Sponsorship 5 November 2024 - £5,250
- A £12,000 charitable contribution was made to the UKMS from the Michael Morley fund in the year 24-25
- UKMRA Away Day January 2025, Principle Hotel in York Sponsorship revenue £33,000 (GSK, J&J, Sanofi x £10k + Amgen £3k)

The Michael Morley Fund

This fund is from a patients estate that is invested on behalf of the UKMS. The Michael Morley funding can be used to fulfil our charitable objectives as agreed with the Michael Morley Trustees.

Investments

CCLA Ethical Charity Investments £56,171

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants' fees and employer's liability insurance). £40,000. Instructed new Accountants, Menzies annual fee £3,200.

UKMS Educational meetings 2024-2025

- Spring and Autumn Education Days Approx £33,191
- UKMS Pharmacy Education Day 5 Nov 24 Wellcome Collection £2,392

UKMRA

- 6th May 24 at the Wellcome Collection - £2,552 inc VAT
- Away Day 16-17 January 2025, Principle Hotel in York

Breakdown of UKMRA Away Day January 2025 Conference Organiser: Hartley Taylor (HT)

Carried forward from 2024	£4,945
Income: Sponsorship raised for 2025	£36,000 (J&J, Sanofi, Pfizer £11k each plus GSK £3k)
Total available for 2025	£40,945
Spend:	£22,902
HT fees:	£16,000
Spend breakdown	
Travel	£5,239
Venue & hotels	£14,375
AV	£2,398
HT travel & hotels	£890
C/F to 2026	£2,042

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Reserves

The UKMF's reserves remain sound as of 31 March 2025 and were approximately £572,469 (2024: £533,823). The investment is held to generate investment income for use within the Charity along with cash used to continue the Charity activities.

Charitable bequests

- Kenneth Nightigale received on 15 October 2025 - £473
- David Owen received on 14 July 2025 - £12,500
- Lyn Nancy Corless received on 13 May 2025 - £5,000
- Martin John Francis Phipps received on 3 October 2025 - £5,000
- Rosemary Ludlam received October 2024 - £1,000
- Andrew Sharpe received November 2024 - £100
- Janice Margaret May: total to date £45,000
- Legacy of £15,000 received on 5 February 2025
- Interim payments followed:
£25,000 received 12 March 2025
£5,000 received on 3 July 2025.

Trustees' responsibilities statement

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on their behalf by:

Signed by:

.....A7B83086CBD1420.....
Dr J Ashcroft
Trustee

Date: 22-Jan-2026

THE UK MYELOMA SOCIETY

MENZIES
BRIGHTER THINKING

INDEPENDENT EXAMINERS' REPORT

Independent examiner's report to the Trustees of The UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2025.

Responsibilities and basis of report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: 
Janice Matthews FCA

Dated: 23-Jan-2026

Menzies LLP
Chartered Accountants
Magna House
18-32 London Road
Staines-Upon-Thames
TW18 4BP

THE UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	Note	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from:				
Donations and legacies	3	183,045	183,045	130,667
Investments	4	7,167	7,167	6,850
Total income		190,212	190,212	137,517
Expenditure on:				
Raising funds	5	1,545	1,545	1,488
Charitable activities	7	150,361	150,361	116,069
Total expenditure		151,906	151,906	117,557
Net income before net gains on investments		38,306	38,306	19,960
Net gains on investments	12	340	340	15,674
Net movement in funds		38,646	38,646	35,634
Reconciliation of funds:				
Total funds brought forward		533,823	533,823	498,189
Net movement in funds		38,646	38,646	35,634
Total funds carried forward		572,469	572,469	533,823

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 16 form part of these financial statements.

THE UK MYELOMA SOCIETY

BALANCE SHEET
AS AT 31 MARCH 2025

	Note	2025 £	2024 £
Fixed assets			
Investments	12	251,532	199,044
		251,532	199,044
Current assets			
Cash at bank and in hand		334,637	347,353
		334,637	347,353
Current liabilities			
Creditors: amounts falling due within one year	13	(13,700)	(12,574)
Net current assets		320,937	334,779
Total assets less current liabilities		572,469	533,823
Total net assets		572,469	533,823
Charity funds			
Designated funds	14	195,361	199,044
General funds	14	377,108	334,779
Total unrestricted funds	14	572,469	533,823
Total funds		572,469	533,823

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Signed by:

.....A7B83086CBD1420.....
Dr J Ashcroft
Trustee

Date: 22-Jan-2026

The notes on pages 9 to 16 form part of these financial statements.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Donations	183,045	183,045	130,667
Total 2024	130,667	130,667	

4. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from listed investments	5,693	5,693	5,366
Interest receivable	1,474	1,474	1,484
	7,167	7,167	6,850
Total 2024	6,850	6,850	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

5. Investment management costs

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Investment management fees	1,545	1,545	1,488
<i>Total 2024</i>	<i>1,488</i>	<i>1,488</i>	

6. Analysis of grants

	Grants to Individuals 2025 £	Total funds 2025 £	Total funds 2024 £
Bursaries granted	8,151	8,151	6,000
<i>Total 2024</i>	<i>6,000</i>	<i>6,000</i>	

7. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2025 £	Total 2025 £	Total 2024 £
Forum expenses	104,514	104,514	69,941
Website costs	5,726	5,726	3,422
Bank charges	260	260	2,094
Staff costs (see note 10)	34,833	34,833	37,132
Accountancy	5,028	5,028	3,480
	150,361	150,361	116,069
<i>Total 2024</i>	<i>116,069</i>	<i>116,069</i>	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

8. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Grant funding of activities 2025 £	Support costs 2025 £	Total funds 2025 £	Total funds 2024 £
Forum expenses	96,363	8,151	-	104,514	69,941
Website costs	5,726	-	-	5,726	3,422
Service charges	260	-	-	260	2,094
Staff costs (see note 10)	-	-	34,833	34,833	37,132
Accountancy	-	-	5,028	5,028	3,480
	102,349	8,151	39,861	150,361	116,069
<i>Total 2024</i>	69,457	6,000	40,612	116,069	

9. Independent examiner's remuneration

	2025 £	2024 £
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	4,800	3,480

10. Staff costs

	2025 £	2024 £
Wages and salaries	34,004	36,357
Contribution to defined contribution pension schemes	829	775
	34,833	37,132

The average number of persons employed by the Charity during the year was as follows:

	2025 No.	2024 No.
Administration	1	1

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During the year ended 31 March 2025, expenses totalling £2,331 were reimbursed or paid directly to 8 Trustees (2024 - £1,604 to 10 Trustees).

12. Fixed asset investments

	Listed investments £	Cash portfolio £	Total £
Cost or valuation			
At 1 April 2024	198,744	300	199,044
Additions	79,846	(19,846)	60,000
Disposals	(29,014)	29,014	-
Revaluations	340	-	340
Funds withdrawn	-	(12,000)	(12,000)
Management fees	-	(1,545)	(1,545)
Dividend and interest income	-	5,693	5,693
At 31 March 2025	249,916	1,616	251,532
Net book value			
At 31 March 2025	249,916	1,616	251,532
At 31 March 2024	198,744	300	199,044

13. Creditors: Amounts falling due within one year

	2025 £	2024 £
Other taxation and social security	1,096	1,544
Pension fund loan payable	333	314
Other creditors	7,471	7,236
Accruals and deferred income	4,800	3,480
	13,700	12,574

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

14. Statement of funds

Statement of funds - current year

	Balance at 1 April 2024 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 March 2025 £
Designated funds						
Michael Morley Investment Fund	199,044	5,693	(1,545)	(12,000)	4,169	195,361
General funds						
General Funds	334,779	184,519	(150,361)	12,000	(3,829)	377,108
Total Unrestricted funds	533,823	190,212	(151,906)	-	340	572,469

Statement of funds - prior year

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 March 2024 £
Designated funds						
Michael Morley Investment Fund	275,492	5,366	(1,488)	(96,000)	15,674	199,044
General funds						
General Funds	222,697	132,151	(116,069)	96,000	-	334,779
Total Unrestricted funds	498,189	137,517	(117,557)	-	15,674	533,823

The designated fund is used to hold the Charity's investments and generate income.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2025 £	Total funds 2025 £
Fixed asset investments	251,532	251,532
Current assets	334,637	334,637
Creditors due within one year	(13,700)	(13,700)
Total	572,469	572,469

Analysis of net assets between funds - prior year

	Unrestricted funds 2024 £	Total funds 2024 £
Fixed asset investments	199,044	199,044
Current assets	347,353	347,353
Creditors due within one year	(12,574)	(12,574)
Total	533,823	533,823

16. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 March 2025.

The UK Myeloma Society

England & Wales - Charity number 1082702

Accounts

TRUSTEES' REPORT AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2024

THE UK MYELOMA
SOCIETY

MENZIES
BRIGHTER THINKING

THE UK MYELOMA SOCIETY

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 - 21

Trustees' Annual Report for the period							
From	Period start date			To	Period end date		
	Day	Month	Year		Day	Month	Year
	1	April	2023		31	March	2024

Section A

Reference and administration details

Charity name	UK Myeloma Society		
Other names charity is known by	UKMS		
Registered charity number (if any)	1082702		
Charity's principal address	Dr John Ashcroft, Treasurer Dept of Haematology Pathology building Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield		
	Postcode	WF1 4DG	

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr Ceri Bygrave (Cardiff)	Chair from November 2023 Wales Representative	November 2023 – November 2025	
2.	Dr Neil Rabin (London)	Past Chair	November 2023 – November 2025	
3.	Dr John Ashcroft (Leeds, Mid Yorks)	Treasurer	November 2023 – November 2026	
4.	Dr Matthew Jenner (Southampton)	Secretary	November 2023 - November 2026	
5.	Dr Rachel Hall (Bournemouth)	Chair Elect	November 2023 -November 2025	
6.	Dr Jonathan Sive (London)	Education Lead	January 2023 -January 2026	
7.	Prof Gordon Cook (Leeds)	Dean of College of Myeloma	November 2019- on going	
8.	Prof Guy Pratt (Birmingham)	Board member	November 2023-November 2026	
9.	Prof Martin Kaiser (London)	Board member	January 2022 – January 2025	

10.	Dr Karthik Ramasamy (Oxford)	Communications Lead	June 2022 - June 2025	
11.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 2020 - November 2024	
12.	Dr Rakesh Popat (London)	Science Lead	November 2021 - November 2024	
13.	Jackie Quinn (Belfast)	Myeloma Nurse Lead	November 2023 -November 2025	
14.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2021 -January 2024	
15.	Dr Jennifer Travers (Glasgow)	Scotland Representative (Invited Board member)	November 2023- November 2026	
16.	Dr Shelly Lawson (Sheffield)	Board member	November 2023 – November 2026	
17.	Catherine Loughran (Leicester)	Board member Pharmacy lead	November 2023-November 2025	
18.	Dr Sally Moore (Bath)	Board member	November 2023-November 2026	
19.	Sophie Castell (Myeloma UK)	Patient/Charity Representative	January 2018-ongoing	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Menzies LLP	Menzies LLP, Richmond House Walkern road, Stevenage, Herts, SG1 3QP
Bankers	Coutts & Co	440 Strand, London, WC2R 0QS

Name of chief executive or names of senior staff members (Optional information)

Section B

Structure, governance and management

Description of the charity’s trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association

Trustee selection methods
(eg. appointed by, elected by)

Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity’s organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees’ consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

- Developing and promoting clinical trials of myeloma treatment and linked scientific studies
- Encouraging collaborative research and innovation in myeloma
- Developing guidelines for the management of patients with myeloma
- Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
- Promoting patient access to treatment through advocacy and working with stakeholders and partners

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMS had a further active year in pursuit of its’ charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2023; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. The main activities undertaken to further its charitable purposes for the public benefit are detailed within this report. There are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue

- Revenue received for corporate sponsorship contributed £123,800 (April 2023-March 2024). This re-enforces the support by pharma for the work that the UKMS undertakes. BMS supported the UKMS by awarding a corporate giving grant of £3,000 in 2024. This ore grant was to support mission and objectives received from Bristol Myers Squibb.
- Separately, £33,000 was raised by Hartley Taylor Medical Communications Ltd from pharma (GSK, J&J, Sanofi x £10k + Amgen £3k) to support for the inaugural UKMRA Away Day on the 16-17 January 2024 in York.
- In additional, £2,610 was raised from Pharma for the inaugural UKMS Pharmacy Education Day on the 23 November 2023 at the Wellcome Collection (Sanofi £500, Pfizer £1,500 and BMS £500 + £110 GSK).

Education

The Autumn Day was held on 9th November 2023, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was ‘Myeloma Management – Beyond the Drugs’and featured Professor Heinz Ludwig from the Wilhelminen Cancer Research Institute in Vienna. He presented the Michael Morley Lecture on ‘Managing infections in the new era of myeloma therapies – prophylaxis, monitoring and treatment’.

The Spring Day was also a hybrid meeting and was held on 20th March 2024. The theme for this meeting was the, ‘Controversies and Uncertainties – Unanswered Questions in Myeloma’. The plenary lecture was given by Professor Niels van der Donk from the Amsterdam University Medical Centre. His talk was entitled, ‘Bispecific Abs and CAR-T: sequencing, toxicities and practicalities’.

Travel Bursaries

A total of six travel bursaries for scientific conferences were awarded in 2023 to winning abstracts.

- 2 x ASH San Diego £1,200 each
- 2 x EHA Frankfurt £900 each
- 2 X IMS Athens £900 each

The abstracts were presented at the subsequent Autumn / Spring Days in either November 2023 or March 2024. A corresponding conference report was also written by the bursary recipients from ASH, EHA and IMS which appeared in the UKMS e-newsletter.

Section D Achievements and performance

Summary of the main achievements of the charity during the year

25 years of the UKMS November 2023-24

In November 2023, the Society began marking its 25 year anniversary. To communicate this, a unique 25 year logo was created and used on all communications throughout the year. A reception held at the Hope Street Hotel in Liverpool for UKMS members, speakers and stakeholders during the BSH Annual meeting on the 29 April 2024 where the Society was invited to host a joint symposium. (Venue and Catering - £1,940).

Section D	Achievements and performance
	Education: The annual meetings Production of two successful and well attended educational hybrid meetings in November 2023 and March 2024. For full programme details, please refer to the section above and the UKMS website. Travel Bursaries for scientific meetings The UKMS in collaboration with the Michael Morley Fund awarded 6 bursaries in 2023-24 to support the attendance of investigators, scientists, specialist nurses and pharmacists at ASH (American Society of Haematology), IMS (International Myeloma Society) and EHA (European Haematology Association) meetings in 2023-24. Further details can be found Section C. Advocacy The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm. The Guidelines group The UKMS Guidelines Group, Chaired by Dr Simon Stern published in 2023 the MGUS good practice paper (GPP). Another GPP on smouldering myeloma was published early in 2024 in the British Journal of Haematology (BJH). GPPs on imaging in myeloma and high risk disease in transplant-eligible myeloma have been completed and accepted by the BSH Haem-onc Task Force and Guidelines Committee. They have both been submitted to the BJH for publication. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients. Other guidelines are work in progress, notably guidelines on the management of relapsed myeloma and a GPP on MGRS. Other guidelines in their early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting. UKMRA - UK Myeloma Research Alliance The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all UK based myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group met three times over the course of the year, twice virtually with one in-person/ hybrid meeting at the Wellcome Collection in central London on the 17th May 2023. On the 25 - 26 January 2024, the UKMRA held the first Away Day at the Principle Hotel in York. Around 30 clinical trial investigators from across the UK held their main group meeting as well as a full day dedicated to developing UK Myeloma related clinical trials. Myeloma Nurse Group Jackie Quinn took over as the Chair of the nurse group from Sarah Henshaw in November 2023. Projects and discussion for the 2023 included; • Develop protocol for Self-administration of Velcade. • Explored the potential for nurse webinars co-partnered with Myeloma UK. • Worked with Myeloma UK to produce a nurse network to support all haematology CNSs across the UK • Haematological Malignancies hybrid Nurse Study Day on 5 July 2023 • In person Nurse Group meeting September 2023 • The group were working with Tracey King, a Haematology nurse from Australia on adapting an online tool Myeloma treatment scheduler called ‘Mye Scheduler’ together the pharmacy group which is tailored to giving full visibility to patients.

Section D

Achievements and performance

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Catherine Loughran will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. On the 23 November 2023, the group held the first Annual Pharmacy Education Day at the Wellcome Collection in central London.

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2023 fellows : Professor Ray Powles CBE
Dr Matthew Streetly
Professor Philippe Moreau

Section E

Financial review

Brief statement of the charity's policy on reserves

The UKMS's policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

Income

- Education Grants from Corporate Sponsors contributed approximately £123,800 in March 2023 - April 2024.
- Income from Pharmacy Day Sponsorship 23 November 2023 - £2,610
- A £12,000 charitable contribution was made to the UKMS from the Michael Morley fund in the year 23-24.
- UKMRA Away Day 16-17 January 2023, Principle Hotel in York Sponsorship revenue £33,000 (GSK, J&J, Sanofi x £10k + Amgen £3k)

The Michael Morley Fund

This fund is from a patient's estate that is invested on behalf of the UKMS. The Michael Morley funding can be used to fulfil our charitable objectives as agreed with the Michael Morley Trustees.

Expenditure

- Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants' fees and employer's liability insurance). £36,000. Instucted new Accountants, Menzies annual fee £1,800+VAT

Educational meetings 2023-2024

- Spring and Autumn Education Days Approx £23,000
- UKMS Pharmacy Education Day 23 Nov 23 Wellcome Collection £1,974.60
- UKMRA f2f meeting 17 May 2024 at the Wellcome Collection £1,567.68

THE UK MYELOMA SOCIETY

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 MARCH 2024

Independent Examiner's Report to the Trustees of The UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2024.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:

Stuart Cuzner

Dated:

ACA FCCA

Menzies LLP Chartered Accountants

Richmond House, Walkern Road
Stevenage
SG1 3QP

THE UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024

	Note	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:				
Donations and legacies	3	130,667	130,667	131,251
Investments	4	6,850	6,850	5,775
Total income		137,517	137,517	137,026
Expenditure on:				
Raising funds	5	1,488	1,488	1,536
Charitable activities	7	116,069	116,069	94,941
Total expenditure		117,557	117,557	96,477
Net income before net gains/(losses) on investments		19,960	19,960	40,549
Net gains/(losses) on investments	12	15,674	15,674	(12,040)
Net movement in funds		35,634	35,634	28,509
Reconciliation of funds:				
Total funds brought forward		498,189	498,189	469,680
Net movement in funds		35,634	35,634	28,509
Total funds carried forward		533,823	533,823	498,189

The Statement of Financial Activities includes all gains and losses recognised in the year.


The notes on pages 12 to 21 form part of these financial statements.

THE UK MYELOMA SOCIETY

BALANCE SHEET
AS AT 31 MARCH 2024

	Note	2024 £	2023 £
Fixed assets			
Investments	12	199,044	191,492
		<u>199,044</u>	<u>191,492</u>
Current assets			
Debtors	13	-	2,799
Cash at bank and in hand		347,353	312,278
		<u>347,353</u>	<u>315,077</u>
Creditors: amounts falling due within one year	14	(12,574)	(8,380)
Net current assets		<u>334,779</u>	<u>306,697</u>
Total assets less current liabilities		<u>533,823</u>	<u>498,189</u>
Total net assets		<u>533,823</u>	<u>498,189</u>
Charity funds			
Designated funds	15	199,044	275,492
General funds	15	334,779	222,697
Total unrestricted funds	15	<u>533,823</u>	<u>498,189</u>
Total funds		<u>533,823</u>	<u>498,189</u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

A7B83086CBD1420.....
Dr J Ashcroft
Trustee

Date: 30-Jan-2025

The notes on pages 12 to 21 form part of these financial statements.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Donations	130,667	130,667	131,251
Total 2023	131,251	131,251	

4. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from listed investments	5,366	5,366	5,351
Interest receivable	1,484	1,484	424
	6,850	6,850	5,775
Total 2023	5,775	5,775	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5. Investment management costs

	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Investment management fees	1,488	1,488	1,536
Total 2023	1,536	1,536	

6. Analysis of grants

	Grants to Individuals 2024 £	Total funds 2024 £	Total funds 2023 £
Bursaries granted	6,000	6,000	7,666
Total 2023	7,666	7,666	

7. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2024 £	Total 2024 £	Total 2023 £
Forum expenses	69,941	69,941	45,907
Website costs	3,422	3,422	13,445
Bank charges	2,094	2,094	3,333
Staff costs (see note 10)	37,132	37,132	29,976
Accountancy (see note 9)	3,480	3,480	2,280
	116,069	116,069	94,941
Total 2023	94,941	94,941	

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

8. Analysis of expenditure by activities

	Activities undertaken directly 2024 £	Grant funding of activities 2024 £	Support costs 2024 £	Total funds 2024 £	Total funds 2023 £
Forum expenses	63,941	6,000	-	69,941	45,907
Website costs	3,422	-	-	3,422	13,445
Service charges	2,094	-	-	2,094	3,333
Staff costs (see note 10)	-	-	37,132	37,132	29,976
Accountancy (see note 9)	-	-	3,480	3,480	2,280
	<u>69,457</u>	<u>6,000</u>	<u>40,612</u>	<u>116,069</u>	<u>94,941</u>
<i>Total 2023</i>	<u>55,019</u>	<u>7,666</u>	<u>32,256</u>	<u>94,941</u>	

9. Independent examiner's remuneration

	2024 £	2023 £
Fees payable to the Company independent examiner for the independent examination of the Company's annual accounts	<u>3,480</u>	<u>2,280</u>

10. Staff costs

	2024 £	2023 £
Wages and salaries	36,357	29,049
Pension costs	775	927
	<u>37,132</u>	<u>29,976</u>

The average number of persons employed by the Charity during the year was as follows:

	2024 No.	2023 No.
Administration	<u>1</u>	<u>1</u>

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

10. Staff costs (continued)

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 March 2024, expenses totalling £1,604 were reimbursed to 10 Trustees (2023 - £933 to 9 Trustees).

12. Fixed asset investments

	Listed investments £	Cash portfolio £	Total £
Cost or valuation			
At 1 April 2023	187,543	3,949	191,492
Additions	13,843	(13,843)	-
Disposals	(18,006)	18,316	310
Revaluations	15,364	-	15,364
Transfers	-	(12,000)	(12,000)
Management fees	-	(1,488)	(1,488)
Dividend and interest income	-	5,366	5,366
At 31 March 2024	198,744	300	199,044
Net book value			
At 31 March 2024	198,744	300	199,044
At 31 March 2023	187,543	3,949	191,492

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

13. Debtors

	2024 £	2023 £
Due within one year		
Other debtors	-	2,799
	-	2,799

14. Creditors: Amounts falling due within one year

	2024 £	2023 £
Trade creditors	-	6,150
Other taxation and social security	1,544	-
Pension fund loan payable	314	130
Other creditors	7,236	-
Accruals and deferred income	3,480	2,100
	12,574	8,380

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

15. Statement of funds

Statement of funds - current year

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 31 March 2024 £
Designated funds						
Michael Morley Investment Fund	275,492	5,366	(1,488)	(96,000)	15,674	199,044
General funds						
General Funds	222,697	132,151	(116,069)	96,000	-	334,779
Total Unrestricted funds	498,189	137,517	(117,557)	-	15,674	533,823

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

15. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 April 2022 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Gains/ (Losses) £</i>	<i>Balance at 31 March 2023 £</i>
Designated funds					
Michael Morley Investment Fund	283,717	5,351	(1,536)	(12,040)	275,492
General funds					
General Funds	185,963	131,675	(94,941)	-	222,697
Total Unrestricted funds	<u>469,680</u>	<u>137,026</u>	<u>(96,477)</u>	<u>(12,040)</u>	<u>498,189</u>

The designated fund is used to hold the Charity's investments and generate income.

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

16. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Total funds 2024 £
Fixed asset investments	199,044	199,044
Current assets	347,353	347,353
Creditors due within one year	(12,574)	(12,574)
Total	533,823	533,823

Analysis of net assets between funds - prior period

	Unrestricted funds 2023 £	Total funds 2023 £
Fixed asset investments	191,492	191,492
Current assets	315,077	315,077
Creditors due within one year	(8,380)	(8,380)
Total	498,189	498,189

17. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 March 2024.

The UK Myeloma Society

England & Wales - Charity number 1082702

Accounts

TRUSTEES' REPORT AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2023

UK MYELOMA SOCIETY

MENZIES
BRIGHTER THINKING

UK MYELOMA SOCIETY

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Notes to the Financial Statements	11 - 19

UK MYELOMA SOCIETY

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2023

Trustees

Dr N Rabin
Dr C Bygrave
Dr R Hall
Dr J Ashcroft
Prof G Cook
Dr G Pratt
Dr M Kaiser
Dr K Ramasamy
Dr S Stern
Dr R Popat
Dr M Jenner
Dr J Sive
S Henshaw
Dr S Lawless
Dr R Soutar
Dr S Lawson
A Preston
S Castell

Charity registered number 1082702

Principal office Pinderfields Hospital
Mid Yorkshire Teaching NHS Trust
Aberford Road
Wakefield
WF1 4DG

Independent examiner Menzies LLP
Chartered Accountants
Richmond House
Walkern Road
Stevenage
Herts
SG1 3QP

Bankers Coutts & Co
440 Strand
London
WC2R 0QS

Trustees' Annual Report for the period

	Period start date				Period end date		
	Day	Month	Year		Day	Month	Year
From	1	April	2022	To	31	March	2023

Section A Reference and administration details

Charity name	UK Myeloma Society		
Other names charity is known by	UKMS		
Registered charity number (if any)	1082702		
Charity's principal address	Dr John Ashcroft, Treasurer Dept of Haematology Pathology building Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield		
	Postcode	WF1 4DG	

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr Neil Rabin (London)	Chair	January 2021 - November 2023	
2.	Dr Ceri Bygrave (Cardiff)	Wales Representative (Invited Board member) Chair Elect Chair from November 2023	November 2015 -November 2023	
3.	Dr Rachel Hall (Bournemouth)	Board Member/Treasurer	November 2019 -November 2023	
4.	Dr John Ashcroft (Leeds, Mid Yorks)	Past Chair / Teasurer	Past Chair – November 2021-November 2023 Treasurer from November 2023	
5.	Prof Gordon Cook (Leeds)	Past Chair/HTA lead/ College of Myeloma Dean	November 2019- on going	
6.	Dr Guy Pratt (Birmingham)	Secretary	November 2002-November 2023	
7.	Dr Martin Kaiser (London)	Board member	January 2019 – January 2025	
8.	Dr Karthik Ramasamy (Oxford)	Communications Lead	June 2020 - June 2025	

9.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 2020 - November 2024	
10.	Dr Rakesh Popat (London)	Science Lead	November 2018 - November 2024	
11.	Dr Matthew Jenner (Southampton)	Board member	March 2019 - March 2023	
12.	Dr Jonathan Sive (London)	Board member	January 2020 -January 2026	
13.	Sarah Henshaw (Nottingham)	Myeloma Nurse Lead	November 2018 -November 2023.	
14.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2018 -January 2024	
15.	Dr Richard Soutar (Glasgow)	Scotland Representative (Invited Board member)	January 2018 -November 2023	
16.	Dr Shelly Lawson (Sheffield)	Board member	January 2020 – January 2026	
17.	Andrea Preston (Bristol)	Board member Pharmacy lead	November 2021-November 2013	
18.	Sophie Castell (Myeloma UK)	Patient/Charity Representative	January 2018-ongoing	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Menzies LLP	Menzies LLP, Richmond House Walkern road, Stevenage, Herts, SG1 3QP
Bankers	Coutts & Co	440 Strand, London, WC2R 0QS

Name of chief executive or names of senior staff members (Optional information)

--

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association
Trustee selection methods (eg. appointed by, elected by)	Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

- Developing and promoting clinical trials of myeloma treatment and linked scientific studies
- Encouraging collaborative research and innovation in myeloma
- Developing guidelines for the management of patients with myeloma
- Promoting knowledge through the education of healthcare professionals and patients in all aspects of the disease
- Promoting patient access to treatment through advocacy and working with stakeholders and partners

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMS had a further active year in pursuit of its' charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2022; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue

Revenue received for corporate sponsorship contributed £129,300 (April 2022-March 2023). This re-enforces the support by pharma for the work that the UKMS undertakes.

Education

The Autumn Day was held on 9th November 2023, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was ‘Precursor states, gaps in data and resource in myeloma management’ and featured Professor Paul G. Richardson from the Dana Farber Cancer Institute, Boston. Prof. Richardson presented the Michael Morley Lecture on ‘Practice-changing data from recent trials.

The Spring Day was also a virtual meeting and was held on 23rd March 2023. The theme for this meeting was the, ‘Personalised Therapy in Myeloma’. The plenary lecture was given by Professor Morie Gertz from the Mayo Clinic in Rochester. His talk was entitled, ‘Diagnosis and therapy of AL amyloidosis in 2023’.

Travel Bursaries

A total of five travel grants for scientific conferences were awarded in 2022 to winning abstracts. Three bursaries of £1,000 each to IMS in Los Angeles in August 2022. The IMS abstracts were presented at the Autumn Day in November 2022. Two bursaries of £1,200 covered the registration fee for ASH (American Society of Haematology Annual Meeting) in San Diego. The ASH abstracts were presented at the Spring Day in March 2023. A conference report written by the bursary recipients from ASH and IMS appeared in the e-newsletter.

Section D

Achievements and performance

Summary of the main achievements of the charity during the year

UKMS rebranding

In November 2022, the UK Myeloma Forum officially rebranded to become the UK Myeloma Society. Following a strategic review, the name change reflected the the growth of the UKMS community. A new logo and website were designed -see www.ukmyelomasociety.org.uk.

Education: The annual meetings

Production of two successful and well attended educational hybrid meetings in November 2022 and March 2023. For full programme details, please refer to the section above and the UKMS website.

Travel Bursaries for scientific meetings

The UKMS in collaboration with the Michael Morley Fund awarded a number of bursaries in 2022-23 to support the attendance of young investigators and specialist nurses at ASH Virtual (American Society of Haematology Meeting) in December 2022. Recipients of the bursaries presented their data at the UKMS Spring Day in March 2023. This is a regular and successful session. For the ASH bursary winners, recipients prepared a short review for the UKMS website and were credited in the UKMS e-newsletter.

Advocacy

The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

Section D

Achievements and performance

The Guidelines group

The UKMS Guidelines Group, Chaired by Dr Simon Stern focused on the management of relapsed myeloma guidelines and the MGUS good practice papers for submission to BSH (British Society of Haematology).

Other guidelines were in various stages of development, notably good practice papers on MGRS and smouldering myeloma. In addition, following discussions at March's Executive meeting, a writing group was formed to produce a good practice paper on imaging in myeloma. The aim was to produce a document that reinforced the importance of functional imaging both at diagnosis and during the later management of myeloma patients.

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group meet virtually twice a year with one face to face meeting planned at the Wellcome Collection on 15th June 22.

Myeloma Nurse Group

The nurse group, Chaired by Sarah Henshaw have worked with MUK reviewing the Nurse Guides that are being reformatted.

Projects for the next 12 months included;

- 1) Self-Administration of bortezomib guidance
- 2) Standardised treatment schedule development - this is a pharmacy group project that the nurse group has supported.
- 3) Working with MUK to set up nurse research plan to do a best practice guide for Peripheral Neuropathy and an audit of the positive aspect that have come out of Covid for nurses in hospitals. The group also worked with Myeloma UK to update and review the nurse guidelines.

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Andrea Preston was newly established in 2021 and launched at the Spring Day in March 2022. The Group will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. See UKMS website for further details.

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2022 fellows : Professor Kwee Yong
Professor Sonja Zweegman
Mr Eric Low OBE

Section E

Financial review

Brief statement of the charity's policy on reserves

The UKMS's policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

Income

Education Grants from Corporate Sponsors contributed approximately £129,300 in March 2022 - April 2023.

A £10,000 charitable contribution was made to the UKMS from the Michael Morley fund in the year 22-23. An additional £5k in 2022 also went to support the website development.

The Michael Morley Fund

This fund is a charitable donation from a patient's estate that is invested on behalf of the UKMS and the interest may be used towards certain projects including supporting two Michael Morley lectures per annum and in 2022 to support the re-branding of the UKMS website.

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants' fees and employer's liability insurance): £32,300.

Spring and Autumn educational meetings in the 22-23 year at approximately £22,515.

- Education Spring Day meeting March 2022 meeting approx £18,000
- UKMRA meeting June 22, Wellcome Collection £1,754
- Website costs £13,000
- Accountants annual fee £2,300

Travel Bursaries 2022

A total of five travel grants for scientific conferences were awarded in 2022 to winning abstracts.

3 x IMS Los Angeles £1,000

2 x ASH San Diego £1,200

Reserves

The UKMF's reserves remain sound as of 31st March 2023 and were £222,697.

Section F Other optional information**Section G Declaration**

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Dr John Ashcroft	
Position (eg Secretary, Chair, etc)	Treasurer	

Date 24-Jan-2024

UK MYELOMA SOCIETY

MENZIES
BRIGHTER THINKING

INDEPENDENT AUDITORS' REPORT TO THE OF UK MYELOMA SOCIETY

Independent Examiner's Report to the Trustees of UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2023.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: 
Stuart Cuzner

Dated: 25-Jan-2024

FCCA ACA

Menzies LLP
Chartered Accountants
Richmond House
Walkern Road
Stevenage
Herts
SG1 3QP

UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2023

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:				
Donations and legacies	3	131,251	131,251	121,320
Investments	4	5,775	5,775	4,285
Total income		137,026	137,026	125,605
Expenditure on:				
Raising funds	5	1,536	1,536	1,633
Charitable activities	6	94,941	94,941	72,984
Total expenditure		96,477	96,477	74,617
Net income before net (losses)/gains on investments		40,549	40,549	50,988
Net (losses)/gains on investments	11	(12,040)	(12,040)	3,863
Net movement in funds		28,509	28,509	54,851
Reconciliation of funds:				
Total funds brought forward		469,680	469,680	414,829
Net movement in funds		28,509	28,509	54,851
Total funds carried forward		498,189	498,189	469,680

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 11 to 19 form part of these financial statements.

UK MYELOMA SOCIETY

BALANCE SHEET AS AT 31 MARCH 2023

	Note	2023 £	2022 £
Fixed assets			
Investments	11	191,492	224,717
		<u>191,492</u>	<u>224,717</u>
Current assets			
Debtors	12	2,799	8,199
Cash at bank and in hand		312,278	248,241
		<u>315,077</u>	<u>256,440</u>
Creditors: amounts falling due within one year	13	(8,380)	(11,477)
Net current assets		<u>306,697</u>	<u>244,963</u>
Total assets less current liabilities		<u>498,189</u>	<u>469,680</u>
Net assets excluding pension asset		<u>498,189</u>	<u>469,680</u>
Total net assets		<u><u>498,189</u></u>	<u><u>469,680</u></u>
Charity funds			
Restricted funds		-	-
Unrestricted funds			
Designated funds		275,492	283,717
General funds		222,697	185,963
Total unrestricted funds	14	<u>498,189</u>	<u>469,680</u>
Total funds		<u><u>498,189</u></u>	<u><u>469,680</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

 A7B63086C8D1420.....
Dr J Ashcroft
 (Trustee)

Date: 24-Jan-2024

The notes on pages 11 to 19 form part of these financial statements.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

2. Accounting policies (continued)

2.4 Expenditure (continued)

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

Investments held as fixed assets are shown at cost less provision for impairment.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

3. Income from donations and legacies

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Donations	131,251	131,251	121,320
<i>Total 2022</i>	121,320	121,320	

4. Investment income

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Income from listed investments	5,351	5,351	4,275
Interest receivable	424	424	10
	5,775	5,775	4,285
<i>Total 2022</i>	4,285	4,285	

5. Raising funds

	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
Investment management fees	1,536	1,536	1,633
<i>Total 2022</i>	1,633	1,633	

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

6. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2023 £	Total 2023 £	Total 2022 £
Forum expenses	45,907	45,907	34,177
Website costs	13,445	13,445	-
Service charges	3,333	3,333	2,814
Staff costs (see note 9)	29,976	29,976	29,819
Accountancy (see note 8)	2,280	2,280	6,174
	<u>94,941</u>	<u>94,941</u>	<u>72,984</u>
<i>Total 2022</i>	<u>72,984</u>	<u>72,984</u>	

7. Analysis of expenditure by activities

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £	Total funds 2022 £
Forum expenses	45,907	-	45,907	34,177
Website costs	13,445	-	13,445	-
Service charges	3,333	-	3,333	2,814
Staff costs (see note 9)	-	29,976	29,976	29,819
Accountancy (see note 8)	-	2,280	2,280	6,174
	<u>62,685</u>	<u>32,256</u>	<u>94,941</u>	<u>72,984</u>
<i>Total 2022</i>	<u>36,991</u>	<u>35,993</u>	<u>72,984</u>	

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

8. Independent examiner's remuneration

	2023 £	2022 £
Fees payable to the Company independent examiner for the independent examination of the Company's annual accounts	2,280	2,640
Fees payable to the Charity's independent examiner in respect of: Accountancy services for the Charity	-	3,534

9. Staff costs

	2023 £	2022 £
Wages and salaries	29,049	29,151
Pension costs	927	668
	29,976	29,819

The average number of persons employed by the Charity during the year was as follows:

	2023 No.	2022 No.
Administration	1	1

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

10. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 31 March 2023, expenses totalling £933 were reimbursed to 9 Trustees (2022 - £1,919 to 9 Trustees).

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

11. Fixed asset investments

	Listed investments £	Cash portfolio £	Total £
Cost or valuation			
At 1 April 2022	208,723	15,994	224,717
Additions	7,532	(7,532)	-
Disposals	(19,308)	16,672	(2,636)
Revaluations	(9,404)	-	(9,404)
Transfers	-	(25,000)	(25,000)
Management fees	-	(1,536)	(1,536)
Dividend and interest income	-	5,351	5,351
At 31 March 2023	187,543	3,949	191,492
Net book value			
At 31 March 2023	187,543	3,949	191,492
At 31 March 2022	208,723	15,994	224,717

12. Debtors

	2023 £	2022 £
Due within one year		
Other debtors	2,799	2,799
Prepayments and accrued income	-	5,400
	2,799	8,199

13. Creditors: Amounts falling due within one year

	2023 £	2022 £
Trade creditors	6,150	-
Pension fund loan payable	130	-
Other creditors	-	4,428
Accruals and deferred income	2,100	7,049
	8,380	11,477

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

14. Statement of funds

Statement of funds - current year

	Balance at 1 April 2022 £	Income £	Expenditure £	Gains/ (Losses) £	Balance at 31 March 2023 £
Designated funds					
Michael Morley Investment Fund	283,717	5,351	(1,536)	(12,040)	275,492
General funds					
General Funds	185,963	131,675	(94,941)	-	222,697
Total Unrestricted funds	469,680	137,026	(96,477)	(12,040)	498,189

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

14. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 April 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Gains/ (Losses) £</i>	<i>Balance at 31 March 2022 £</i>
Designated funds					
Michael Morley Investment Fund	277,212	4,275	(1,633)	3,863	283,717
General funds					
General Funds	137,617	121,330	(72,984)	-	185,963
Total Unrestricted funds	<u>414,829</u>	<u>125,605</u>	<u>(74,617)</u>	<u>3,863</u>	<u>469,680</u>

The designated fund is used to hold the Charity's investments and generate income.

UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2023

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £	Total funds 2023 £
Fixed asset investments	191,492	191,492
Current assets	315,077	315,077
Creditors due within one year	(8,380)	(8,380)
Total	498,189	498,189

Analysis of net assets between funds - prior year

	Unrestricted funds 2022 £	Total funds 2022 £
Fixed asset investments	224,717	224,717
Current assets	256,440	256,440
Creditors due within one year	(11,477)	(11,477)
Total	469,680	469,680

16. Related party transactions

There were no disclosable related party transactions during the year (2022 - none).

The UK Myeloma Society

England & Wales - Charity number 1082702

Accounts

UK MYELOMA FORUM
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

UK MYELOMA FORUM

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Prof G Cook
Dr J Ashcroft
Dr N Rabin
Dr G Pratt
Dr M Kaiser
Dr K Ramasamy
Dr S Stern
Dr R Popat
Dr M Jenner
S Henshaw
Dr S Lawless
Dr R Soutar
Dr R Hall
Dr J Sive
Dr S Lawson
Dr C Bygrave

Charity number

1082702

Principal address

Royal Bournemouth Hospital
Castle Lane East
Bournemouth
BH7 7DW

Independent examiner

Joel Courts
c/o HW Fisher LLP
Chartered Accountants
Acre House
11-15 William Road
London
NW1 3ER

Bankers

Coutts & Co
440 Strand
London
WC2R 0QS

UK MYELOMA FORUM

CONTENTS

	Page
Trustees' report	1 - 6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the accounts	10 - 17

Trustees' Annual Report for the period						
From	Period start date			To	Period end date	
	Day	Month	Year		Day	Month
	1	April	2021		31	March 2022

Section A Reference and administration details

Charity name	UK Myeloma Forum
Other names charity is known by	UKMF
Registered charity number (if any)	1082702
Charity's principal address	Royal Bournemouth Hospital
	Castle Lane East
	Bournemouth
Postcode	BH7 7DW

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr John Ashcroft (Leeds, Mid Yorks)	Chair / Board member	Chair November 2019 - November 2021	
2.	Dr Rachel Hall (Bournemouth)	Board Member/Treasurer	November 2019 -November 2023	
3.	Prof Gordon Cook (Leeds)	Past Chair/HTA lead	November 2019- November 2021	
4.	Dr Neil Rabin (London)	Chair Elect	January 2019 - November 2021	
5.	Prof Guy Pratt (Birmingham)	Secretary	November 2002-November 2023	
6.	Dr Martin Kaiser (London)	Board member	January 2019 – January 2022	
7.	Dr Karthikeyan Ramasamy (Oxford)	Communications Lead	June 2020 - June 2022	
8.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 202 - June 2023	
9.	Dr Rakesh Popat (London)	Science Lead	November 2018 - November 2021	
10.	Dr Matthew Jenner (Southampton)	Board member	March 2019 - March 2022	

11.	Dr Jonathan Sive (London)	Board member	January 2020 -January 2023	
12.	Sarah Henshaw (Nottingham)	Myeloma Nurse Lead	November 2018 -November 2021	
13.	Dr Ceri Bygrave (Cardiff)	Wales Representative (Invited Board member)	November 2015 -November 2021	
14.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2018 -January 2024	
15.	Dr Richard Soutar (Glasgow)	Scotland Representative (Invited Board member)	January 2018 -January 2024	
16.	Dr Michelle Lawson (Sheffield)	Board member	January 2020 – January 2023	
17.	Laura Kerby (Myeloma UK)	Patient/Charity Representative	January 2018-November 2021	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Joel Courts, HW Fisher LLP	Acre House 11-15 William Road London NW1 3ER
Bankers	Coutts & Co	440 Strand London WC2R 0QS

Name of chief executive or names of senior staff members (Optional information)

--

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association
Trustee selection methods (eg. appointed by, elected by)	Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The Charity's objects ("the objects") are

1. The advancement of education of the general public, in particular in the treatment of those suffering from myeloma and related disorders, through the promotion and conduct of research and the publication and dissemination of all useful results of such research.
2. The relief of persons suffering from myeloma and related disorders, in particular by
 - a) the development and provision of policy guidelines for their treatment
 - b) promoting an understanding of the issues relating to myeloma and related disorders by encouraging communication and the exchange of information between research groups and healthcare professionals.

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMF had a further active year in pursuit of its charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held in 2021-2022; June 2021, November 2021 and March 2022.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue received for corporate sponsorship contributed £121,320 (April 2021-March 2022). This re-enforces the support by pharma for the work that the UKMF undertakes.

The Autumn Day was held on 11th November 2021, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was 'Sequencing Therapy and Personalised Medicine in Myeloma' and featured Professor Faith Davies from NYU Grossman School of Medicine, New York. Prof. Davies presented the Michael Morley Lecture on 'My current approach to sequencing therapy in myeloma and how this can be refined with personalised therapy'.

The Spring Day was also a virtual meeting and was held on 16th March 2022. The theme for this meeting was the, 'Relapsed Myeloma and the Impact of Covid-19'. The plenary lecture was given by Dr Vincent Rajkumar from the Mayo Clinic in Rochester. His talk was entitled, 'How I treat relapsed myeloma: a global perspective'.

A total of eight travel grants for scientific conferences were awarded in 2021 to winning abstracts. Three bursaries of £140 each to EHA Virtual in June 2021. The EHA abstracts were presented at the Autumn Day in November 2021. Five bursaries of £450 covered the registration fee for ASH (American Society of Haematology Annual Meeting). The ASH abstracts were presented at the Spring Day in March 2022. A review of ASH was produced in the e-newsletter.

Section D

Achievements and performance

Summary of the main achievements of the charity during the year

The annual meetings

Producing two successful and well attended educational hybrid meetings in November 2021 and March 2022. For full programme details, please refer to the section above and the UKMF website.

Travel grants for scientific meetings

The UKMF awarded a number of bursaries in 2021-22 at EHA Virtual in June 2021 and ASH Atlanta (American Society of Haematology Meeting) in December 2021.

Advocacy

The UKMF members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMF also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

The Guidelines group

The UKMF Guidelines Group, Chaired by Dr Simon Stern remained active despite the difficulties caused by the Covid-19 pandemic, good progress had been made on the development of 2 new separate sets of guidelines on the management of both newly diagnosed and relapsed multiple myeloma.

A full first draft of the newly diagnosed guidelines had been reviewed by the BSH Haemato-oncology Task Force and BSH Guidelines Committee. A first full draft of the relapsed guidelines was near completion.

In addition, writing groups had been set up with a view to producing Good Practice Papers (GPPs) on the diagnosis and management of both MGUS and MGRS.

Section D

Achievements and performance

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group meet virtually twice a year with one face to face meeting planned at the Wellcome Collection on 15th June 22.

Myeloma Nurse Group

The nurse group, Chaired by Sarah Henshaw plan to do a best practice guide for Peripheral Neuropathy and an audit of the positive aspect that have come out of Covid for nurses in hospitals. The group are also working with Myeloma UK to update and review the nurse guidelines.

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Andrea Preston was newly established in 2021 and launched at the Spring Day in March 22. The Group will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMF work-plan, and aim to standardise clinical practice across the UK. There are 11 core members.

College of Myeloma (UK)

Created in 2019, the College of Myeloma (UK) consists of elected fellows representing those who have contributed significantly to the work of the UKMF and to patients with Myeloma through medical science, education and clinical care.

2021 fellows : Professor Mark Cook
Professor Graham Jackson
Dr Jenny Bird

Section E

Financial review

Brief statement of the charity's policy on reserves

The UKMF's policy on reserves is to maintain sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any

Income

Education Grants from Corporate Sponsors contributed £121,320, April 2021 - March 2022.

The Michael Morley Fund

This fund is a charitable donation from a patient's estate that is invested on behalf of the UKMF and the interest may be used towards certain projects including supporting two Michael Morley lectures per annum. See section D for further details).

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Administrative Secretary, accountants' fees, employer's liability insurance and teleconferencing).

ethical investment policy adopted.

Spring and Autumn educational meetings in the 21-22 year at £22,515.

Travel bursaries to ASH 2021 = £450 x 5 each

Travel bursaries to EHA 2021= £140 x 3 each

Website redevelopment deposit = £5,400

Reserves

The UKMF's free reserves remain sound as of 31st March 2022 and were approximately £185,963.

Section F

Other optional information

--

Section G

Declaration

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)

R Hall

Full name(s)

Dr Rachel Hall

Position (eg Secretary, Chair, etc)

Treasurer

Date

14 Mar 2023

UK MYELOMA FORUM

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF UK MYELOMA FORUM

I report to the trustees on my examination of the financial statements of UK Myeloma Forum (the charity) for the year ended 31 March 2022.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Joel Courts

Joel Courts
c/o HW Fisher LLP
Chartered Accountants
Acre House
11-15 William Road
London
NW1 3ER

14 Mar 2023

Dated:

UK MYELOMA FORUM

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2022

		Unrestricted funds general 2022	Unrestricted funds designated 2022	Total 2022	Unrestricted funds general 2021	Unrestricted funds designated 2021	Total 2021
	Notes	£	£	£	£	£	£
Income from:							
Donations and legacies	3	121,320	-	121,320	133,560	-	133,560
Investments	4	10	4,275	4,285	29	4,334	4,363
Total income		121,330	4,275	125,605	133,589	4,334	137,923
Expenditure on:							
Raising funds	5	-	1,633	1,633	-	1,436	1,436
Charitable activities	6	72,984	-	72,984	53,329	-	53,329
Total resources expended		72,984	1,633	74,617	53,329	1,436	54,765
Net gains/(losses) on investments	11	-	3,863	3,863	-	41,166	41,166
Net movement in funds		48,346	6,505	54,851	80,260	44,064	124,324
Fund balances at 1 April 2021		137,617	277,212	414,829	57,357	233,148	290,505
Fund balances at 31 March 2022		185,963	283,717	469,680	137,617	277,212	414,829

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

UK MYELOMA FORUM

BALANCE SHEET

AS AT 31 MARCH 2022

	Notes	2022 £	£	2021 £	£
Fixed assets					
Investments	12		224,717		218,212
Current assets					
Debtors	13	8,199		283	
Cash at bank and in hand		248,241		202,392	
		256,440		202,675	
Creditors: amounts falling due within one year	14	(11,477)		(6,058)	
Net current assets			244,963		196,617
Total assets less current liabilities			469,680		414,829
Income funds					
Unrestricted funds - designated	15		283,717		277,212
Unrestricted funds - general			185,963		137,617
			469,680		414,829

14 Mar 2023

The financial statements were approved by the Trustees on



.....
Dr Rachel Hall
Trustee

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

Charity information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Department of Haematology, Royal Bournemouth Hospital, Bournemouth, Dorset, BH14 9QN

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Interest receivable on fixed interest securities and cash deposits is accrued.

1.5 Resources expended

Liabilities are recognised as expenditure once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of generating funds consist of investment management fees.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs, are allocated to the one charitable activity in the statement of financial activities.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

1 Accounting policies

(Continued)

1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.7 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any critical accounting estimates or judgements applied in the preparation of the financial statements.

3 Donations and legacies

	Unrestricted funds general 2022 £	Unrestricted funds general 2021 £
Donations	121,320	133,560

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

4 Investments

	Unrestricted funds general 2022 £	Unrestricted funds designated 2022 £	Total 2022 £	Unrestricted funds general 2021 £	Unrestricted funds designated 2021 £	Total 2021 £
Investment income	10	4,275	4,285	29	4,334	4,363
	<u>10</u>	<u>4,275</u>	<u>4,285</u>	<u>29</u>	<u>4,334</u>	<u>4,363</u>

5 Raising funds

	2022 £	2021 £
Investment management fees	1,633	1,436
	<u>1,633</u>	<u>1,436</u>

6 Charitable activities

	2022 £	2021 £
Forum expenses	34,177	17,217
Management fees	144	650
	<u>34,321</u>	<u>17,867</u>
Grant funding of activities (see note 7)	2,670	1,050
Share of support costs (see note 8)	29,819	27,932
Share of governance costs (see note 8)	6,174	6,480
	<u>72,984</u>	<u>53,329</u>
Analysis by fund		
Unrestricted funds - general	<u>72,984</u>	<u>53,329</u>

7 Grants payable

	2022 £	2021 £
Grants to individuals	2,670	1,050
	<u>2,670</u>	<u>1,050</u>

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

8 Support costs

	Support costs	Governance costs	2022	Support costs	Governance costs	2021
	£	£	£	£	£	£
Staff costs	29,819	-	29,819	27,932	-	27,932
Accountancy	-	6,174	6,174	-	6,480	6,480
	<u>29,819</u>	<u>6,174</u>	<u>35,993</u>	<u>27,932</u>	<u>6,480</u>	<u>34,412</u>
Analysed between						
Charitable activities	<u>29,819</u>	<u>6,174</u>	<u>35,993</u>	<u>27,932</u>	<u>6,480</u>	<u>34,412</u>

Governance costs includes payments to the independent examiner of £2,640 (2021: £2,640) for independent examination fees and £3,534 (2021: £3,840) for accountancy services.

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year. During the year, travelling expenses of £1,919 (2021: Nil) were reimbursed to 9 trustees.

10 Employees

The average monthly number employees during the year was.

	2022 Number	2021 Number
Administration	<u>1</u>	<u>1</u>
Employment costs	2022	2021
	£	£
Wages and salaries	29,151	27,312
Other pension costs	668	620
	<u>29,819</u>	<u>27,932</u>

Key management personnel are the trustees and they received no remuneration during the current or prior year.

There were no employees whose annual remuneration was £60,000 or more.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

11 Net gains/(losses) on investments

	Unrestricted funds designated 2022 £	Unrestricted funds designated 2021 £
Revaluation of investments	3,739	38,443
Gain/(loss) on sale of investments	124	2,723
	<u>3,863</u>	<u>41,166</u>

12 Fixed asset investments

	Listed investments £	Cash in portfolio £	Total £
Cost or valuation			
At 1 April 2021	201,862	16,350	218,212
Additions	22,269	(22,269)	-
Valuation changes	3,739	-	3,739
Dividend and interest received	-	4,275	4,275
Management fee	-	(1,633)	(1,633)
Disposals	(19,147)	19,271	124
	<u>208,723</u>	<u>15,994</u>	<u>224,717</u>
At 31 March 2022	208,723	15,994	224,717
Carrying amount			
At 31 March 2022	<u>208,723</u>	<u>15,994</u>	<u>224,717</u>
At 31 March 2021	<u>201,862</u>	<u>16,350</u>	<u>218,212</u>

13 Debtors

	2022 £	2021 £
Amounts falling due within one year:		
Other debtors	2,799	283
Prepayments	5,400	-
	<u>8,199</u>	<u>283</u>

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

14 Creditors: amounts falling due within one year

	2022 £	2021 £
Other creditors	4,428	178
Accruals	7,049	5,880
	11,477	6,058

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

15 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds					Movement in funds				
	Balance at 1 April 2020	Incoming resources	Resources expended	Revaluations, gains and losses	Balance at 1 April 2021	Incoming resources	Resources expended	Revaluations, gains and losses	Balance at 31 March 2022	
	£	£	£	£	£	£	£	£	£	
Michael Morley Investment Fund	233,148	4,334	(1,436)	41,166	277,212	4,275	(1,633)	3,863	283,717	
	<u>233,148</u>	<u>4,334</u>	<u>(1,436)</u>	<u>41,166</u>	<u>277,212</u>	<u>4,275</u>	<u>(1,633)</u>	<u>3,863</u>	<u>283,717</u>	

The designated fund is used to hold the Charity's investments and generate income.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2022

16 Analysis of net assets between funds

	Unrestricted 2022 £	Designated 2022 £	Total 2022 £	Unrestricted 2021 £	Designated 2021 £	Total 2021 £
Fund balances at 31 March 2022 are represented by:						
Investments	-	224,717	224,717	-	218,212	218,212
Current assets/(liabilities)	185,963	59,000	244,963	137,617	59,000	196,617
	<u>185,963</u>	<u>283,717</u>	<u>469,680</u>	<u>137,617</u>	<u>277,212</u>	<u>414,829</u>

17 Analysis of changes in net funds

The charity had no debt during the year.

18 Related party transactions

There were no disclosable related party transactions during the year (2021 - none).

The UK Myeloma Society

England & Wales - Charity number 1082702

Accounts

UK MYELOMA FORUM
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

UK MYELOMA FORUM

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Prof G Cook
Dr J Ashcroft
Dr N Rabin
Dr G Pratt
Dr M Kaiser
Dr K Ramasamy
Dr S Stern
Dr R Popat
Dr M Jenner
S Henshaw
Dr S Lawless
Dr R Soutar
Dr R Hall
Dr J Sive
Dr S Lawson
Dr M Streetly
Dr C Bygrave
L Kerby

Charity number

1082702

Principal address

Royal Bournemouth Hospital
Castle Lane East
Bournemouth
BH7 7DW

Independent examiner

Joel Courts
c/o HW Fisher LLP
Chartered Accountants
Acre House
11-15 William Road
London
NW1 3ER

Bankers

Adam & Co
25 St Andrew Square
Edinburgh
EH2 1AF

UK MYELOMA FORUM

CONTENTS

	Page
Trustees' report	1 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the accounts	11 - 17

Trustees' Annual Report for the period							
From	Period start date			To	Period end date		
	Day	Month	Year		Day	Month	Year
	1	April	2020		31	March	2021

Section A Reference and administration details

Charity name	UK Myeloma Forum		
Other names charity is known by	UKMF		
Registered charity number (if any)	1082702		
Charity's principal address	Royal Bournemouth Hospital		
	Castle Lane East		
	Bournemouth		
Postcode	BH7 7DW		

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1.	Dr John Ashcroft (Leeds, Mid Yorks)	Chair / Board member	Chair November 2015 - November 2021	
2.	Dr Rachel Hall (Bournemouth)	Board Member/Treasurer	November 2019 -November 2023	
3.	Prof Gordon Cook (Leeds)	Past Chair/HTA lead	November 2019- November 2021	
4.	Dr Neil Rabin (London)	Chair Elect	January 2013 - November 2021	
5.	Dr Guy Pratt (Birmingham)	Secretary	November 2013-November 2023	
6.	Dr Martin Kaiser (London)	Board member	January 2018 – January 2022	
7.	Dr Karthik Ramasamy (Oxford)	Communications Lead	November 2014 - June 2022	
8.	Dr Simon Stern (Surrey)	Guidelines Secretary	June 2017 - June 2023	
9.	Dr Matthew Streetly (London)	Advocacy lead	January 2014 - January 2020	
10.	Dr Rakesh Popat (London)	Science Lead	November 2018 - November 2021	
11.	Dr Matthew Jenner (Southampton)	Board member	March 2018 - March 2022	

12.	Dr Jonathan Sive (London)	Board member	January 2020 -January 2023	
13.	Sarah Henshaw (Nottingham)	Myeloma Nurse Lead	November 2018 -November 2021	
14.	Dr Ceri Bygrave (Cardiff)	Wales Representative (Invited Board member)	November 2015 -November 2021	
15.	Dr Sarah Lawless (N.Ireland)	N.Ireland Representative (Invited Board member)	January 2018 -January 2024	
16.	Dr Richard Soutar (Glasgow)	Scotland Representative (Invited Board member)	December 2017 -January 2024	
17.	Dr Michelle Lawson (Sheffield)	Board member	January 2020 – January 2023	

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Joel Courts, HW Fisher LLP	Acre House 11-15 William Road London NW1 3ER
Bankers	Adam & Co	25 St Andrew Square, Edinburgh, EH2 1AF

Name of chief executive or names of senior staff members (Optional information)

--

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Association
Trustee selection methods (eg. appointed by, elected by)	Elected from membership

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

The Charity's objects ("the objects") are

1. The advancement of education of the general public, in particular in the treatment of those suffering from myeloma and related disorders, through the promotion and conduct of research and the publication and dissemination of all useful results of such research.
2. The relief of persons suffering from myeloma and related disorders, in particular by
 - a) the development and provision of policy guidelines for their treatment
 - b) promoting an understanding of the issues relating to myeloma and related disorders by encouraging communication and the exchange of information between research groups and healthcare professionals.

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

The UKMF had a further active year in pursuit of its' charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held in 2020-2021; June 2020, November 2020 and March 2021.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. These are summarised in the following pages.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Revenue for corporate sponsorship contributed £133,560 (April 2020-March 2021). This re-enforces the support by pharma for the work that the UKMF undertakes.

Due to Covid-19, the Autumn Day became an entirely virtual meeting and was held on 11th November 2020. The programme theme was 'Accelerating Research: Better Trial Designs, Better Therapies' and featured Professor Mohamad Mohty from Saint Antoine Research Centre, Paris. Prof. Mohty presented the Michael Morley Lecture on 'A journey from past to future'.

The Spring Day was also a virtual meeting and was held on 17th March 2021. The theme for this meeting was the, 'Impact of Covid on Multiple Myeloma Management'. The plenary lecture was given by Dr Maheshi Ramasamy from the University of Oxford. Her talk was entitled, 'The Oxford Astra Zeneca vaccine-developing a global vaccine against COVID-19.

A number of travel grants for scientific conferences were awarded in 2020 to winning abstracts. Three bursaries of £350 covered the registration fee for ASH (American Society of Haematology Annual Meeting). This meeting was virtual due to Covid-19 travel restrictions. The ASH abstracts were presented at the Spring Day in March 2021. A review of ASH was produced in the e-newsletter. Initially, two travel grants of £700 were awarded to attend the EMN meeting (European Myeloma Network) from 16th -18th April 2020 in Amsterdam. However, this meeting was cancelled and later postponed to March 2021 due to the global pandemic. The bursary funds have been returned to the UKMF.

Section D

Achievements and performance

Summary of the main achievements of the charity during the year

The annual meetings

Producing two successful and well attended educational meetings on a new virtual platform in November 2020 and March 2021. For details, please refer to the section above and the UKMF website for programme and talks from these meetings.

Please refer to the UKMF website for the programme and talks from the education meeting.

Travel grants for scientific meetings

The UKMF in collaboration with the Michael Morley Fund awarded a number of bursaries in 2020-21 to support the attendance of young investigators and specialist nurses at ASH Virtual (American Society of Haematology Meeting) in December 2020. Recipients of the bursaries presented their data at the UKMF Spring Day in March 2021. This is a regular and successful session. For the ASH bursary winners, recipients prepared a short review for the UKMF website and were credited in the UKMF e-newsletter.

Advocacy

The UKMF members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMF also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

The Guidelines group

The UKMF Guidelines Group remained active despite the difficulties caused by the Covid-19 pandemic, good progress had been made on the development of 2 new separate sets of guidelines on the management of both newly diagnosed and relapsed multiple myeloma.

A full first draft of the newly diagnosed guidelines had been reviewed by the BSH Haemato-oncology Task Force and BSH Guidelines Committee. A first full draft of the relapsed guidelines was near completion.

In addition, writing groups had been set up with a view to producing Good Practice Papers (GPPs) on the diagnosis and management of both MGUS and MGRS.

Myeloma Nurse Group

Due to COVID, the Nurse group understandably had not been as active in 2020. However, the group planned to pull together details on the impact of COVID to Myeloma Nursing Care in preparation for the Spring Day 2021. The nurse group also planned to do a best practice guide for Peripheral Neuropathy.

College of Myeloma (UK)

Created in 2019, the College of Myeloma (UK) consists of elected fellows representing those who have contributed significantly to the work of the UKMF and to patients with Myeloma through medical science, education and clinical care.

- Fellows will be nominated and elected to the College.
- Elected fellows will be known as Fellows of the College of Myeloma (UK) and can use the designation of F.C.My.(UK), should they wish.
- The College will be led by a Dean (Professor Gordon Cook), elected from the College fellowship on a 3 yearly basis.
- The aim is to elect one fellow per year.
 - two fellows will be elected each year for the first 5 years
 - then one per year afterwards.
 - Until the College has a core of fellows, the UKMF Executive committee shall vote on the nominees for each year.

The election process will be coordinated by the sitting past-Chair of the UKMF, both in the first five years of establishing the College, and thereafter thus ensuring the continually engagement and involvement by the UKMF in the establishment of the College

The Fellows of the College will provide guidance to the Society in order for the Society to deliver on its organisational strategy. Consequently, Fellows of the College will serve to:

- Individually, provide expert input to the delivery of medical education, either through advice on content or the provision of content in line with the UKMF Education strategy.
- Individually, provide mentorship for developing professionals in the field of plasma cell disorders, to assist in career development.
- Individually, where appropriate, assist in the governance of the clinical research program as directed by the Society's research strategy delivered through the UK Myeloma Research Alliance
- Collectively provide advice and guidance on patient advocacy in accordance with the Society's advocacy strategy.
- Collectively provide support and guidance on matters of public policy, health technology appraisals and national service delivery strategies as affect patients with myeloma.

2019 fellows : Professor Curly Morris
Professor Kwee Yong

2020 fellows : Professor Keith Stewart
Professor Steve Schey

2021 fellows: Professor Graham Jackson
Dr Jenny Bird
Professor Mark Cook

Section E Financial review

Brief statement of the charity's policy on reserves

The UKMF's policy on reserves is to maintain sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

Income

Education Grants from Corporate Sponsors contributed £133,560 in the year 2020-2021. £68,261 was received in 2019-2020.

Micheal Morley fund at the end of the 2020-2021 tax year stood at £277,212 compared to £233,148 in the previous year.

Total income from the 2020-2021 year was £137,923 (2020: £73,859).

The Michael Morley Fund

This fund is a charitable donation from a patient's estate that is invested on behalf of the UKMF and the interest may be used towards certain projects including supporting two Michael Morley lectures per annum. See section D for further details).

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Administrative Secretary, accountants' fees, employer's liability insurance and teleconferencing) at £34,412 (2020: £34,291).

Spring and Autumn educational meetings in the 20-21 year at £17,217 (2020: £44,730).

Travel bursaries to ASH 2020 amounting to £1,050 (2020: £6,000).

Reserves

The UKMF's unrestricted reserves remain sound as of 31st March 2021 and were approximately £137,617 (2020: £57,357).

Section F Other optional information

Section G Declaration

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Dr Rachel Hall	
Position (eg Secretary, Chair, etc)	Treasurer	
Date	28 Jan 2022	

UK MYELOMA FORUM

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF UK MYELOMA FORUM

I report to the trustees on my examination of the financial statements of UK Myeloma Forum (the charity) for the year ended 31 March 2021.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Joel Courts

Joel Courts
c/o HW Fisher LLP
Chartered Accountants
Acre House
11-15 William Road
London
NW1 3ER

28 Jan 2022

Dated:

UK MYELOMA FORUM

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2021

		Unrestricted funds general 2021 £	Unrestricted funds designated 2021 £	Total 2021 £	Unrestricted funds general 2020 £	Unrestricted funds designated 2020 £	Total 2020 £
	Notes						
Income from:							
Donations and legacies	3	133,560	-	133,560	68,261	-	68,261
Investments	4	29	4,334	4,363	301	5,297	5,598
Total income		133,589	4,334	137,923	68,562	5,297	73,859
Expenditure on:							
Raising funds	5	-	1,436	1,436	-	1,542	1,542
Charitable activities	6	53,329	-	53,329	85,896	-	85,896
Total resources expended		53,329	1,436	54,765	85,896	1,542	87,438
Net gains/(losses) on investments	11	-	41,166	41,166	-	(27,595)	(27,595)
Net movement in funds		80,260	44,064	124,324	(17,334)	(23,840)	(41,174)
Fund balances at 1 April 2020		57,357	233,148	290,505	74,691	256,988	331,679
Fund balances at 31 March 2021		137,617	277,212	414,829	57,357	233,148	290,505

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

UK MYELOMA FORUM

BALANCE SHEET

AS AT 31 MARCH 2021

	Notes	2021 £	£	2020 £	£
Fixed assets					
Investments	12		218,212		174,148
Current assets					
Debtors	13	283		1,430	
Cash at bank and in hand		202,392		162,266	
		<u>202,675</u>		<u>163,696</u>	
Creditors: amounts falling due within one year	14	<u>(6,058)</u>		<u>(47,339)</u>	
Net current assets			196,617		116,357
Total assets less current liabilities			<u>414,829</u>		<u>290,505</u>
Income funds					
Unrestricted funds - designated	15		277,212		233,148
Unrestricted funds - general			137,617		57,357
			<u>414,829</u>		<u>290,505</u>

28 Jan 2022

The financial statements were approved by the Trustees on



Dr Rachel Hall

Trustee

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

1 Accounting policies

Charity information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the definition of a public benefit entity under FRS 102. The registered office is Department of Haematology, Royal Bournemouth Hospital, Bournemouth, Dorset, BH14 9QN

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

The trustees have considered the effect of the prolonged Covid-19 outbreak. The trustees consider that the outbreak is unlikely to cause significant disruption to the charity's activities and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements. The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Interest receivable on fixed interest securities and cash deposits is accrued.

1.5 Resources expended

Liabilities are recognised as expenditure once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of generating funds consist of investment management fees.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs, are allocated to the one charitable activity in the statement of financial activities.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

1 Accounting policies

(Continued)

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.7 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any critical accounting estimates or judgements applied in the preparation of the financial statements.

3 Donations and legacies

	Unrestricted funds general 2021 £	Unrestricted funds general 2020 £
Donations	133,560	68,261

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

4 Investments

	Unrestricted funds general 2021 £	Unrestricted funds designated 2021 £	Total 2021 £	Unrestricted funds general 2020 £	Unrestricted funds designated 2020 £	Total 2020 £
Investment income	29	4,334	4,363	301	5,297	5,598

5 Raising funds

	2021 £	2020 £
Investment management fees	1,436	1,542
	1,436	1,542

6 Charitable activities

	2021 £	2020 £
Forum expenses	17,217	44,730
Management fees	650	875
	17,867	45,605
Grant funding of activities (see note 7)	1,050	6,000
Share of support costs (see note 8)	27,932	26,677
Share of governance costs (see note 8)	6,480	7,614
	53,329	85,896
Analysis by fund		
Unrestricted funds - general	53,329	85,896

7 Grants payable

	2021 £	2020 £
Grants to individuals	1,050	6,000
	1,050	6,000

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

8 Support costs

	Support costs	Governance costs	2021	Support costs	Governance costs	2020
	£	£	£	£	£	£
Staff costs	27,932	-	27,932	26,677	-	26,677
Accountancy	-	6,480	6,480	-	7,614	7,614
	<u>27,932</u>	<u>6,480</u>	<u>34,412</u>	<u>26,677</u>	<u>7,614</u>	<u>34,291</u>
Analysed between						
Charitable activities	<u>27,932</u>	<u>6,480</u>	<u>34,412</u>	<u>26,677</u>	<u>7,614</u>	<u>34,291</u>

Governance costs includes payments to the independent examiner of £2,640 (2020: £2,520) for independent examination fees and £3,840 (2020: £5,094) for accountancy services.

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year whereas 10 of the trustees were reimbursed £3,313 for travel expenses in 2020.

10 Employees

Number of employees

The average monthly number employees during the year was.

	2021 Number	2020 Number
Administration	<u>1</u>	<u>1</u>
Employment costs	2021	2020
	£	£
Wages and salaries	27,312	26,068
Other pension costs	620	609
	<u>27,932</u>	<u>26,677</u>

Key management personnel are the trustees and they received no remuneration during the current or prior year.

There were no employees whose annual remuneration was £60,000 or more in the current or prior year.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

11 Net gains/(losses) on investments

	Unrestricted funds designated 2021 £	Unrestricted funds designated 2020 £
Revaluation of investments	38,443	(28,984)
Gain/(loss) on sale of investments	2,723	1,389
	<u>41,166</u>	<u>(27,595)</u>

12 Fixed asset investments

	Listed investments £	Cash in portfolio	Total £
Cost or valuation			
At 1 April 2020	161,955	12,193	174,148
Additions	18,657	(18,657)	-
Valuation changes	38,443	-	38,443
Dividend and interest received	-	4,334	4,334
Management fee	-	(1,436)	(1,436)
Disposals	(17,193)	19,916	2,723
	<u>201,862</u>	<u>16,350</u>	<u>218,212</u>
At 31 March 2021	201,862	16,350	218,212
	<u>201,862</u>	<u>16,350</u>	<u>218,212</u>
Carrying amount			
At 31 March 2021	201,862	16,350	218,212
	<u>201,862</u>	<u>16,350</u>	<u>218,212</u>
At 31 March 2020	161,955	12,193	174,148
	<u>161,955</u>	<u>12,193</u>	<u>174,148</u>

13 Debtors

	2021 £	2020 £
Amounts falling due within one year:		
Other debtors	283	1,430
	<u>283</u>	<u>1,430</u>

14 Creditors: amounts falling due within one year

	2021 £	2020 £
Other taxation and social security	-	1,439
Other creditors	178	-
Accruals and deferred income	5,880	45,900
	<u>6,058</u>	<u>47,339</u>

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

15 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds				Movement in funds				
	Balance at 1 April 2019	Incoming resources	Resources expended	Revaluations, gains and losses	Balance at 1 April 2020	Incoming resources	Resources expended	Revaluations, gains and losses	Balance at 31 March 2021
	£	£	£	£	£	£	£	£	£
Michael Morley Investment Fund	256,988	5,297	(1,542)	(27,595)	233,148	4,334	(1,436)	41,166	277,212
	<u>256,988</u>	<u>5,297</u>	<u>(1,542)</u>	<u>(27,595)</u>	<u>233,148</u>	<u>4,334</u>	<u>(1,436)</u>	<u>41,166</u>	<u>277,212</u>

The designated fund is used to hold the Charity's investments and generate income.

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

16 Analysis of net assets between funds

	Unrestricted	Designated	Total	Unrestricted	Designated	Total
	2021	2021	2021	2020	2020	2020
	£	£	£	£	£	£
Fund balances at 31 March 2021 are represented by:						
Investments	-	218,212	218,212	-	174,148	174,148
Current assets/(liabilities)	137,617	59,000	196,617	57,357	59,000	116,357
	<u>137,617</u>	<u>277,212</u>	<u>414,829</u>	<u>57,357</u>	<u>233,148</u>	<u>290,505</u>

17 Analysis of changes in net funds

The charity had no debt during the year.

18 Related party transactions

There were no disclosable related party transactions during the year (2020 - none).